Page 1

voyager therapeutics Voyager Reports Second Quarter 2026 Financial and Operating Results -VY7523 clinical data and VY1706 clinical entry , both in Alzheimer's , expected Q4 2026 - - Ended Q2 2026 with cash position of $ 149 million , runway into 2028 - LEXINGTON , Mass . , August 6 , 2026 -- Voyager Therapeutics , Inc. ( Nasdaq VYGR ) , a biotechnology company dedicated to leveraging genetics to treat neurological diseases , today reported second quarter 202 financial and operating results . " We view tau as a critical disease - modifying target in Alzheimer's disease , and we believe recent third - party data validate this hypothesis , ” said Alfred W. Sandrock , Jr. , M.D. , Ph.D. , Chief E ecutive Officer of Voyager . " We continue to advance our two tau - targeted programs toward potential inflection points in clinical trials for Alzheimer's disease before the end of the year , with the tau - targeted antibody VY7523 e pected to generate tau PET imaging data and the tau - targeted gene therapy VY170 e pected to begin dosing . " Second Quarter 2026 and Recent Highlights • VY7523 anti - tau antibody ) : Voyager e ( pects tau positron emission tomography PET ) imaging efficacy data in Q4 202 from the ongoing multiple ascending dose ( clinical trial in participants with Alzheimer's disease ( AD ) . • VY1706 tau silencing gene therapy ) : The U.S. Food and Drug Administration ( Investigational New Drug ( the United States . Dosing is e • • • MAD ) FDA ) cleared Voyager's IND ) application , enabling initiation of a clinical trial in adults with early AD in pected to begin Q4 202 In July , Health Canada cleared Voyager's Clinical Trial Application ( of Canadian clinical trial sites in the study . CTA ) , enabling the inclusion NBIB - ' 223 Friedreich's ataxia gene therapy ) : Voyager's partner Neurocrine Biosciences has stated that it intends to initiate a clinical trial with NBIB - ‘ 223 in H2 202 , pending successful FDA IND clearance . to Developing Topics poster at AAIC 2026 : Voyager presented -month good laboratory practice ( icology non - human primate ( GLP ) NHP ) data showing VY170 was well tolerated and resulted in sustained tau protein reduction by up to 75 % in key AD brain regions following a single intravenous IV ) dose . ( ? Eight presentations at ASGCT 2026 Voyager's presentations included a late - breaking oral presentation on 3 - month GLP to icology data for VY170 , an oral presentation on muscular and neuromuscular capsid variants , and multiple poster presentations . Anticipated Upcoming Milestones • Q4 202 VY170 e • Q4 202 • H2 202 • • pected to begin dosing in adults with early AD VY7523 tau PET imaging data e pected in MAD clinical trial in AD Neurocrine intends to initiate a clinical trial with NBIB - ' 223 for Friedreich's ata pending successful FDA IND clearance Early 2027 Potential for initial acute safety data with VY170 , pending enrollment H2 2027 Potential for initial biomarker - based data for VY170 , pending enrollment ני ני г ני ני г ני ia ,